PDS Biotechnology Corp (PDSB): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:05 ET
- Event date
- 2026-11-13
- Accession no.
- 0001140361-26-043542
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
PDS Biotech reports third quarter 2026 results and PIPE financing update
PDS Biotech reported a net loss of $7.6 million for the quarter ended September 30, 2026, compared to $9.0 million a year earlier. Cash and cash equivalents were $15.2 million. The company also reported the initial closing of a PIPE financing of up to $22.3 million and continued prioritization of PDS0301 as its lead development program.
- Net loss was $7.6 million, or $0.11 per basic and diluted share, versus $9.0 million, or $0.19 per share, a year earlier.
- Cash and cash equivalents were $15.2 million as of September 30, 2026.
- Research and development expenses were $2.1 million, compared to $4.6 million a year earlier.
- The company completed the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC.
earningsfinancing
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | ef20085528_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | ef20085528_ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.